Research map: Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications
Back to the article
Papers in this map
A global reference for human genetic variation
· Corresponding authors · 2015 · 20479 citations · Cited by this paper
Relationships among nitrous oxide exposure, neurological injury and biomarkers
· 2026 · Related
Guidance for conducting systematic scoping reviews
· Micah D.J. Peters · 2015 · 7762 citations · Cited by this paper
Predicting cognitive function in Alzheimer's clinical trials via amyloid β‐protein biomarkers
· 2026 · Related
The Genetic Structure and History of Africans and African Americans
· Sarah A. Tishkoff · 2009 · 1618 citations · Cited by this paper
Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population‐based cohort study
· 2026 · Related
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
· Sharon Lynn Walmsley · 2013 · 894 citations · Cited by this paper
MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)
· 2026 · Related
Human Extrahepatic Cytochromes P450: Function in Xenobiotic Metabolism and Tissue-Selective Chemical Toxicity in the Respiratory and Gastrointestinal Tracts
· Xinxin Ding · 2003 · 821 citations · Cited by this paper
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus
· 2026 · Related
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
· S P H Alexander · 2021 · 487 citations · Cited by this paper
Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025
· 2026 · Related
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes
· S P H Alexander · 2021 · 389 citations · Cited by this paper
Analysis of spontaneous reports of suspected adverse reactions related to medical cannabis from the Italian Phytovigilance System
· 2026 · Related
Expression and Regulation of Xenobiotic-Metabolizing Cytochrome P450 (CYP) Enzymes in Human Lung
· Janne Hukkanen · 2002 · 318 citations · Cited by this paper
A university‐certified course on dossier assessment for regulatory scientists in Africa—Reporting on our 5‐year experience
· 2026 · Related
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
· Christian Hoffmann · 2016 · 292 citations · Cited by this paper
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis
· 2025 · Related
In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor
· Melinda J. Reese · 2012 · 252 citations · Cited by this paper
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing
· RS Gammal · 2015 · 232 citations · Cited by this paper
Pharmacogenomics
· Dan M. Roden · 2011 · 223 citations · Cited by this paper
Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice
· Mark G. J. de Boer · 2016 · 183 citations · Cited by this paper
PXR: A Xenobiotic Receptor of Diverse Function Implicated in Pharmacogenetics
· Bin Zhang · 2008 · 159 citations · Cited by this paper
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters
· S P H Alexander · 2021 · 153 citations · Cited by this paper
Emerging roles for folate and related B-vitamins in brain health across the lifecycle
· C. McGarel · 2014 · 144 citations · Cited by this paper
Adverse events of raltegravir and dolutegravir
· Luigia Elzi · 2017 · 125 citations · Cited by this paper
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors
· S P H Alexander · 2021 · 122 citations · Cited by this paper
Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors
· Christian Hoffmann · 2019 · 116 citations · Cited by this paper
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
· Rulan Griesel · 2020 · 89 citations · Cited by this paper
Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits
· Joseph Maranville · 2015 · 80 citations · Cited by this paper
Cellular Zinc Levels Are Modulated by TRPML1–TMEM163 Interaction
· Math P. Cuajungco · 2014 · 61 citations · Cited by this paper
Overview of Genotyping Technologies and Methods
· Ingrid Skelton Kockum · 2023 · 59 citations · Cited by this paper
Evaluation of the Effect of UGT1A1 Polymorphisms on Dolutegravir Pharmacokinetics
· Shuguang Chen · 2013 · 58 citations · Cited by this paper
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens
· Michael A. Leonard · 2020 · 56 citations · Cited by this paper
Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin
· Xinzhu Wang · 2019 · 50 citations · Cited by this paper
Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight
· Carrie McMahon · 2020 · 40 citations · Cited by this paper
High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants
· K. Tsuchiya · 2017 · 35 citations · Cited by this paper
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV
· Alberto Borghetti · 2018 · 31 citations · Cited by this paper
Conference Scene: The Great Debate: Genome-Wide Association Studies in Pharmacogenetics Research, Good or Bad?
· Kent R. Bailey · 2010 · 17 citations · Cited by this paper
Source: OpenAlex (CC0)